The efficacy and safety of using pyrotinib combined with capecitabine as neoadjuvant therapy in elderly patients with HER2-positive breast cancer: a single-arm prospective clinical trial

BACKGROUND: Pyrotinib combined with capecitabine has been approved for the treatment of patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer in China. To date, the management of early-stage or locally advanced HER2-positive breast cancer in the clinic remai...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Wei, Zhang, Juan, Chang, Jin-Yi, Yao, De-Shun, Hu, Fen, Liang, Yong-Ping, Shen, Yan, Liu, Yu-Qi, Qi, Huai-Hua, Tong, Jian-Bin, Cai, Hai-Feng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10005991/
https://www.ncbi.nlm.nih.gov/pubmed/36915823
http://dx.doi.org/10.21037/gs-23-11

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10005991/
https://www.ncbi.nlm.nih.gov/pubmed/36915823
http://dx.doi.org/10.21037/gs-23-11

Ejemplares similares